You’re absolutely right! Scratch my idea about repositioning Telcyta as an economic savior for Medicare—your idea is 10 times better.
Think of how many drugs could have succeeded in phase-3 trials if only the placebos hadn’t performed so well. Well, now trial designers have a brand new option: compare your drug head-to-head vs Telcyta for overall survival!
TELK ought to be able to sell a billion dollars worth for this indication.
News 
Market Data 
Discover 
